France (FR)

Apremilast Treatment and Long-Term (156-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Pooled Analysis of a Large Database of 3 Phase III, Randomized, Controlled Trials (2016) Gladman DD, Kavanaugh A, Gomez-Reino JJ, Wollenhaupt J, Cutolo M, Schett G, Lespessailles E, et al. Conference contribution APREMILAST, AN ORAL PHOSPHODIESTERASE-4 INHIBITOR, IS ASSOCIATED WITH LONG-TERM (104-WEEK) IMPROVEMENTS IN ENTHESITIS AND DACTYLITIS IN PATIENTS WITH PSORIATIC ARTHRITIS: POOLED RESULTS FROM THREE PHASE III RANDOMIZED CONTROLLED TRIALS (2016) Gladman DD, Kavanaugh A, Adebajo AO, Gomez-Reino JJ, Wollenhaupt J, Cutolo M, Schett G, et al. Conference contribution Apremilast, an Oral Phosphodiesterase 4 Inhibitor, is Associated with Long-term (104-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Pooled Results from Three Phase III, Randomized, Controlled Trials (2016) Gladman D, Kavanaugh A, Adebajo A, Gomez-Reino J, Wollenhaupt J, Cutolo M, Schett G, et al. Conference contribution On a Boltzmann mean field model for knowledge growth (2016) Burger M, Lorz A, Wolfram MT Journal article Soluble CD83 inhibits skin inflammation to chemical sensitizers (2016) Mihatsch P, Boyd P, Krzyzak L, Lechmann M, Nicolas J, Mahler V, Steinkasserer A, Vocanson M Conference contribution THE EUROPEAN SOCIAL PREFERENCE MEASUREMENT (ESPM) STUDY: CONCEPTUAL CONSIDERATIONS AND IMPLEMENTATION (2016) Schlander M, Telser H, Holm S, Marshall DA, Nord E, Richardson J, Garattini S, et al. Conference contribution Novel nanosystems to combat atherosclerosis: Functional effects on human endothelial and monocytic cells (2016) Cicha I, Matuszak J, Juenet M, Chauvierre C, Texier I, Almer G, Prassl R, et al. Conference contribution TREAT CTC: An innovative therapy approach to eliminate circulating tumor cells (CTCs) (2016) Tzschaschel M, Trapp E, Rack B, Messina C, Mueller V, Fehm T, Janni W, et al. Conference contribution Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab (2016) Weide B, Martens A, Hassel JC, Berking C, Postow MA, Bisschop K, Simeone E, et al. Journal article Final results of a self-apposing paclitaxel-eluting stent fOr the PErcutaNeous treatment of de novo lesions in native bifurcated coronary arteries study (2016) Naber CK, Pyxaras SA, Nef H, Ijsselmuiden AJ, Briguori C, Schlundt C, Wykrzykowska J, et al. Journal article